Effects of growth hormone on fuel utilization and muscle glycogen synthase activity in normal humans.
To examine the insulin antagonistic effects of growth hormone (GH), seven healthy subjects underwent, in random order, two 5-h euglycemic clamp studies with moderate hyperinsulinemia. A GH infusion (45 ng.kg-1.min-1) was given throughout one of the studies. GH inhibited the insulin-stimulated glucose disposal by 27% from 4.4 +/- 0.7 to 3.3 +/- 0.4 mg.kg-1.min-1 (P less than 0.02) and raised the nonprotein energy expenditures (NPEE) from 18.7 +/- 0.5 to 20.5 +/- 0.3 kcal.kg-1.24 h-1 (P less than 0.03). Lipid oxidation contributed 71.7 +/- 5.6% of NPEE during the GH infusion as compared with 48.7 +/- 5.2% during the control clamp (P less than 0.02). In skeletal muscle biopsies, insulin binding to wheat germ agglutinin-purified insulin receptors and insulin receptor kinase activity were unaffected by GH infusion. Glycogen synthase activation by insulin was inhibited by 41% during the GH clamp (fractional velocity 14.1 +/- 2.5 vs. 8.3 +/- 1.4%, P less than 0.03). In conclusion, GH 1) increases energy expenditures and inhibits glucose oxidation in favor of an increased lipid oxidation, and 2) inhibits insulin-mediated activation of the glycogen synthase in skeletal muscle biopsies by a mechanism distal to insulin receptor binding and kinase activity.